NYXH
Nyxoah S.A.
Medical - Instruments & Supplies
Market Cap$52M
5Y Perf.-94.2%
Build Your Comparison
Side-by-side financial analysisNYXH
LIVN
JPM
NVCR
GKOS
Try popular comparisons:
Stock Comparison
NYXH vs LIVN vs JPM vs NVCR vs GKOS
Revenue, margins, valuation, and 5-year total return — side by side.
LIVN
LivaNova PLC
Medical - Devices
Market Cap$4.36B
5Y Perf.-6.5%
JPM
JPMorgan Chase & Co.
Banks - Diversified
Market Cap$896.00B
5Y Perf.+108.5%
NVCR
NovoCure Limited
Medical - Instruments & Supplies
Market Cap$2.02B
5Y Perf.-91.3%
GKOS
Glaukos Corporation
Medical - Devices
Market Cap$7.42B
5Y Perf.+34.7%
NYXH vs LIVN vs JPM vs NVCR vs GKOS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  NYXH |  LIVN |  JPM |  NVCR |  GKOS |
|---|---|---|---|---|---|
| Industry | Medical - Instruments & Supplies | Medical - Devices | Banks - Diversified | Medical - Instruments & Supplies | Medical - Devices |
| Market Cap | $52M | $4.36B | $896.00B | $2.02B | $7.42B |
| Revenue (TTM) | $16M | $1.43B | $280.33B | $674M | $551M |
| Net Income (TTM) | $-86M | $107M | $57.05B | $-173M | $-189M |
| Gross Margin | 48.3% | 67.5% | 60.0% | 75.2% | 78.1% |
| Operating Margin | -5.3% | 13.4% | 25.9% | -27.2% | -15.6% |
| Forward P/E | — | 18.7x | 14.4x | — | — |
| Total Debt | $42M | $473M | $942.38B | $290M | $140M |
| Cash & Equiv. | $30M | $636M | $343.34B | $103M | $91M |
NYXH vs LIVN vs JPM vs NVCR vs GKOS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
NYXH
LIVN
JPM
NVCR
GKOS
| Stock | Apr 21 | Jun 26 | Return |
|---|---|---|---|
| Nyxoah S.A. (NYXH) | 100 | 5.8 | -94.2% |
| LivaNova PLC (LIVN) | 100 | 93.5 | -6.5% |
| JPMorgan Chase & Co. (JPM) | 100 | 208.5 | +108.5% |
| NovoCure Limited (NVCR) | 100 | 8.7 | -91.3% |
| Glaukos Corporation (GKOS) | 100 | 134.7 | +34.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: NYXH vs LIVN vs JPM vs NVCR vs GKOS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: JPM leads in 4 of 7 categories (5-stock set), making it the strongest pick for valuation and capital efficiency and profitability and margin quality. LivaNova PLC is the stronger pick specifically for recent price momentum and sentiment and operational efficiency and capital deployment. NYXH also leads in specific categories worth noting. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
🥇JPM emerged as the overall leader. Track its performance:
NYXH
Nyxoah S.A.
The Growth Play
NYXH ranks third and is worth considering specifically for growth exposure.
- Rev growth 121.6%, EPS growth -30.9%, 3Y rev CAGR 48.1%
- 121.6% revenue growth vs JPM's 3.3%
Best for: growth exposure
LIVN
LivaNova PLC
The Momentum Pick
LIVN is the #2 pick in this set and the best alternative if momentum and efficiency is your priority.
- +70.3% vs NYXH's -81.6%
- 4.2% ROA vs NYXH's -80.8%, ROIC 11.5% vs -76.4%
Best for: momentum and efficiency
JPM
JPMorgan Chase & Co.
The Banking Pick
JPM carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 15 yrs, beta 0.94, yield 1.9%
- 465.8% 10Y total return vs GKOS's 379.3%
- Better valuation composite
- 20.4% margin vs NYXH's -5.3%
Best for: income & stability and long-term compounding
NVCR
NovoCure Limited
The Healthcare Pick
NVCR lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
GKOS
Glaukos Corporation
The Defensive Pick
GKOS is the clearest fit if your priority is sleep-well-at-night and defensive.
- Lower volatility, beta 1.01, Low D/E 21.3%, current ratio 4.69x
- Beta 1.01, current ratio 4.69x
Best for: sleep-well-at-night and defensive
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  NYXH | 121.6% revenue growth vs JPM's 3.3% |
| Value |  JPM | Better valuation composite |
| Quality / Margins | JPM | 20.4% margin vs NYXH's -5.3% |
| Stability / Safety | JPM | Beta 0.94 vs NVCR's 2.21 |
| Dividends | JPM | 1.9% yield; 15-year raise streak; the other 4 pay no meaningful dividend |
| Momentum (1Y) |  LIVN | +70.3% vs NYXH's -81.6% |
| Efficiency (ROA) | LIVN | 4.2% ROA vs NYXH's -80.8%, ROIC 11.5% vs -76.4% |
NYXH vs LIVN vs JPM vs NVCR vs GKOS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
FY 2025
Segment breakdown not available.
FY 2019
NYXH vs LIVN vs JPM vs NVCR vs GKOS — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLJPMLAGGINGGKOS
Who Leads Where
JPM leads in 3 of 6 categories
LIVN leads 1 • NYXH leads 0 • NVCR leads 0 • GKOS leads 0 • 1 tied
Explore the data ↓GKOSGlaukos Corporation
0leads
NVCRNovoCure Limited
0leads
NYXHNyxoah S.A.
0leads
LIVNLivaNova PLC
1leads
JPMJPMorgan Chase & Co.
3leads
6 Total Categories
CATEGORYLEADERvs LIVNvs NYXHMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
JPM3/6
Valuation MetricsMultiples, price ratios, and targets
JPM2/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
LIVN6/9
Total Returns1Y, 3Y, 5Y total returns with dividends
JPM4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
JPM leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
JPM is the larger business by revenue, generating $280.3B annually — 17179.4x NYXH's $16M. JPM is the more profitable business, keeping 20.4% of every revenue dollar as net income compared to NYXH's -5.3%. On growth, NYXH holds the edge at +5.9% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | NYXHNyxoah S.A. | LIVNLivaNova PLC | JPMJPMorgan Chase & … |  NVCRNovoCure Limited |  GKOSGlaukos Corporati… |
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $16M | $1.4B | $280.3B | $674M | $551M |
| EBITDAEarnings before interest/tax | -$81M | $220M | $81.4B | -$165M | -$40M |
| Net IncomeAfter-tax profit | -$86M | $107M | $57.0B | -$173M | -$189M |
| Free Cash FlowCash after capex | -$73M | $161M | $100.9B | -$48M | -$18M |
| Gross MarginGross profit ÷ Revenue | +48.3% | +67.5% | +60.0% | +75.2% | +78.1% |
| Operating MarginEBIT ÷ Revenue | -5.3% | +13.4% | +25.9% | -27.2% | -15.6% |
| Net MarginNet income ÷ Revenue | -5.3% | +7.5% | +20.4% | -25.7% | -34.3% |
| FCF MarginFCF ÷ Revenue | -4.5% | +11.2% | +36.0% | -7.1% | -3.4% |
| Rev. Growth (YoY)Latest quarter vs prior year | +5.9% | +14.3% | — | +12.3% | +41.2% |
| EPS Growth (YoY)Latest quarter vs prior year | +38.3% | +106.7% | +16.0% | -100.0% | -6.3% |
JPM leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
JPM leads this category, winning 2 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, LIVN's 17.4x EV/EBITDA is more attractive than JPM's 18.4x.
| Metric | NYXHNyxoah S.A. | LIVNLivaNova PLC | JPMJPMorgan Chase & … | NVCRNovoCure Limited | GKOSGlaukos Corporati… |
|---|---|---|---|---|---|
| Market CapShares × price | $52M | $4.4B | $896.0B | $2.0B | $7.4B |
| Enterprise ValueMkt cap + debt − cash | $66M | $4.2B | $1.50T | $2.2B | $7.5B |
| Trailing P/EPrice ÷ TTM EPS | -0.51x | -17.84x | 16.00x | -14.57x | -38.66x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 18.68x | 14.40x | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | 0.90x | — | — |
| EV / EBITDAEnterprise value multiple | — | 17.39x | 18.36x | — | — |
| Price / SalesMarket cap ÷ Revenue | 4.48x | 3.14x | 3.20x | 3.09x | 14.63x |
| Price / BookPrice ÷ Book value/share | 0.93x | 3.61x | 2.47x | 5.82x | 11.05x |
| Price / FCFMarket cap ÷ FCF | — | 25.18x | 8.88x | — | — |
JPM leads this category, winning 2 of 6 comparable metrics.
Profitability & Efficiency
LIVN leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
JPM delivers a 15.9% return on equity — every $100 of shareholder capital generates $16 in annual profit, vs $-164 for NYXH. GKOS carries lower financial leverage with a 0.21x debt-to-equity ratio, signaling a more conservative balance sheet compared to JPM's 2.60x. On the Piotroski fundamental quality scale (0–9), LIVN scores 5/9 vs NYXH's 2/9, reflecting solid financial health.
| Metric | NYXHNyxoah S.A. | LIVNLivaNova PLC | JPMJPMorgan Chase & … | NVCRNovoCure Limited | GKOSGlaukos Corporati… |
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -164.4% | +9.1% | +15.9% | -50.8% | -26.5% |
| ROA (TTM)Return on assets | -80.8% | +4.2% | +1.3% | -16.5% | -20.1% |
| ROICReturn on invested capital | -76.4% | +11.5% | +4.5% | -16.4% | -9.2% |
| ROCEReturn on capital employed | -80.4% | +10.2% | +8.9% | -28.9% | -10.3% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 5 | 5 | 5 | 3 |
| Debt / EquityFinancial leverage | 0.86x | 0.39x | 2.60x | 0.85x | 0.21x |
| Net DebtTotal debt minus cash | $12M | -$162M | $599.0B | $187M | $49M |
| Cash & Equiv.Liquid assets | $30M | $636M | $343.3B | $103M | $91M |
| Total DebtShort + long-term debt | $42M | $473M | $942.4B | $290M | $140M |
| Interest CoverageEBIT ÷ Interest expense | -32.73x | 5.18x | 0.74x | -96.80x | -18.69x |
LIVN leads this category, winning 6 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
JPM leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in JPM five years ago would be worth $21,820 today (with dividends reinvested), compared to $515 for NYXH. Over the past 12 months, LIVN leads with a +70.3% total return vs NYXH's -81.6%. The 3-year compound annual growth rate (CAGR) favors JPM at 33.6% vs NYXH's -44.0% — a key indicator of consistent wealth creation.
| Metric | NYXHNyxoah S.A. | LIVNLivaNova PLC | JPMJPMorgan Chase & … | NVCRNovoCure Limited | GKOSGlaukos Corporati… |
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -69.1% | +30.9% | -0.5% | +35.5% | +14.5% |
| 1-Year ReturnPast 12 months | -81.6% | +70.3% | +21.8% | -2.3% | +29.9% |
| 3-Year ReturnCumulative with dividends | -82.4% | +65.4% | +138.2% | -59.8% | +89.5% |
| 5-Year ReturnCumulative with dividends | -94.9% | -2.8% | +118.2% | -91.9% | +57.4% |
| 10-Year ReturnCumulative with dividends | -94.2% | +62.7% | +465.8% | +62.1% | +379.3% |
| CAGR (3Y)Annualised 3-year return | -44.0% | +18.3% | +33.6% | -26.2% | +23.7% |
JPM leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — LIVN and JPM each lead in 1 of 2 comparable metrics.
Risk & Volatility
JPM is the less volatile stock with a 0.94 beta — it tends to amplify market swings less than NVCR's 2.21 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LIVN currently trades 98.3% from its 52-week high vs NYXH's 16.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | NYXHNyxoah S.A. | LIVNLivaNova PLC | JPMJPMorgan Chase & … | NVCRNovoCure Limited | GKOSGlaukos Corporati… |
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.10x | 1.23x | 0.94x | 2.21x | 1.01x |
| 52-Week HighHighest price in past year | $8.59 | $80.73 | $337.25 | $18.92 | $148.11 |
| 52-Week LowLowest price in past year | $1.26 | $41.02 | $262.71 | $9.82 | $73.16 |
| % of 52W HighCurrent price vs 52-week peak | +16.2% | +98.3% | +95.1% | +94.0% | +85.6% |
| RSI (14)Momentum oscillator 0–100 | 25.8 | 69.4 | 59.1 | 57.1 | 51.4 |
| Avg Volume (50D)Average daily shares traded | 189K | 727K | 7.0M | 1.5M | 859K |
Evenly matched — LIVN and JPM each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: NYXH as "Buy", LIVN as "Buy", JPM as "Buy", NVCR as "Buy", GKOS as "Buy". Consensus price targets imply 331.7% upside for NYXH (target: $6) vs -0.2% for LIVN (target: $79). JPM is the only dividend payer here at 1.86% yield — a key consideration for income-focused portfolios.
| Metric | NYXHNyxoah S.A. | LIVNLivaNova PLC | JPMJPMorgan Chase & … | NVCRNovoCure Limited | GKOSGlaukos Corporati… |
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $6.00 | $79.25 | $339.75 | $33.50 | $149.00 |
| # AnalystsCovering analysts | 5 | 14 | 61 | 15 | 24 |
| Dividend YieldAnnual dividend ÷ price | — | — | +1.9% | — | — |
| Dividend StreakConsecutive years of raises | — | — | 15 | — | — |
| Dividend / ShareAnnual DPS | — | — | $5.95 | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.1% | +3.9% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
JPM leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). LIVN leads in 1 (Profitability & Efficiency). 1 tied.
Best OverallJPMorgan Chase & Co. (JPM)Leads 3 of 6 categories
Loading custom metrics...
NYXH vs LIVN vs JPM vs NVCR vs GKOS: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is NYXH or LIVN or JPM or NVCR or GKOS a better buy right now?
For growth investors, Nyxoah S.
A. (NYXH) is the stronger pick with 121. 6% revenue growth year-over-year, versus 3. 3% for JPMorgan Chase & Co. (JPM). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 0x trailing P/E (14. 4x forward), making it the more compelling value choice. Analysts rate Nyxoah S. A. (NYXH) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — NYXH or LIVN or JPM or NVCR or GKOS?
On forward P/E, JPMorgan Chase & Co.
is actually cheaper at 14. 4x.
03Which is the better long-term investment — NYXH or LIVN or JPM or NVCR or GKOS?
Over the past 5 years, JPMorgan Chase & Co.
(JPM) delivered a total return of +118. 2%, compared to -94. 9% for Nyxoah S. A. (NYXH). Over 10 years, the gap is even starker: JPM returned +465. 8% versus NYXH's -94. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — NYXH or LIVN or JPM or NVCR or GKOS?
By beta (market sensitivity over 5 years), JPMorgan Chase & Co.
(JPM) is the lower-risk stock at 0. 94β versus NovoCure Limited's 2. 21β — meaning NVCR is approximately 134% more volatile than JPM relative to the S&P 500. On balance sheet safety, Glaukos Corporation (GKOS) carries a lower debt/equity ratio of 21% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.
05Which is growing faster — NYXH or LIVN or JPM or NVCR or GKOS?
By revenue growth (latest reported year), Nyxoah S.
A. (NYXH) is pulling ahead at 121. 6% versus 3. 3% for JPMorgan Chase & Co. (JPM). On earnings-per-share growth, the picture is similar: NovoCure Limited grew EPS 21. 8% year-over-year, compared to -483. 6% for LivaNova PLC. Over a 3-year CAGR, NYXH leads at 48. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — NYXH or LIVN or JPM or NVCR or GKOS?
JPMorgan Chase & Co.
(JPM) is the more profitable company, earning 20. 4% net margin versus -899. 1% for Nyxoah S. A. — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus -827. 8% for NYXH. At the gross margin level — before operating expenses — GKOS leads at 77. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is NYXH or LIVN or JPM or NVCR or GKOS more undervalued right now?
On forward earnings alone, JPMorgan Chase & Co.
(JPM) trades at 14. 4x forward P/E versus 18. 7x for LivaNova PLC — 4. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NYXH: 331. 7% to $6. 00.
08Which pays a better dividend — NYXH or LIVN or JPM or NVCR or GKOS?
In this comparison, JPM (1.
9% yield) pays a dividend. NYXH, LIVN, NVCR, GKOS do not pay a meaningful dividend and should not be held primarily for income.
09Is NYXH or LIVN or JPM or NVCR or GKOS better for a retirement portfolio?
For long-horizon retirement investors, JPMorgan Chase & Co.
(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 94), 1. 9% yield, +465. 8% 10Y return). Nyxoah S. A. (NYXH) carries a higher beta of 2. 10 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JPM: +465. 8%, NYXH: -94. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between NYXH and LIVN and JPM and NVCR and GKOS?
These companies operate in different sectors (NYXH (Healthcare) and LIVN (Healthcare) and JPM (Financial Services) and NVCR (Healthcare) and GKOS (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: NYXH is a small-cap high-growth stock; LIVN is a small-cap quality compounder stock; JPM is a large-cap deep-value stock; NVCR is a small-cap quality compounder stock; GKOS is a small-cap high-growth stock. JPM pays a dividend while NYXH, LIVN, NVCR, GKOS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.